Intensive insulin treatment and postprandial control in Type 1 diabetes

Acta Biomedica de l'Ateneo Parmense

Volumn 76, Issue SUPPL. 3, 2005, Pages 26-30

  Aragona, Michele ^a   Giannarelli, Rosa ^a   Del Prato, Stefano ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTAME; GLULYSINE INSULIN; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; GLYCOSYLATED HEMOGLOBIN;

CONFERENCE PAPER; DIABETES CONTROL; DISEASE SEVERITY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LOW DRUG DOSE; POSTPRANDIAL STATE; ARTICLE; BLOOD; DIABETES MELLITUS; HYPOGLYCEMIA; MOTIVATION; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; GOALS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; POSTPRANDIAL PERIOD;

EID: 33750094597     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Banting F, Campbell WR, Fletcher AA. Further clinical experience with insulin (pancreatic extracts) in the treatment of diabetes mellitus. British Medical Journal 1923; 8-12.
2. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl. J Med 1993; 329: 977-86.
3. The Diabetes Control and Complications Trial. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44 (8): 968-83.
4. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care 2003; 26 (10): 2728-33.
5. Li W, Liu X, Yanoff M, Cohen S, Ye X. Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 1996; 39: 537-47.
6. Del Prato S, Tiengo A. The importance of fisrt-phase insulin secretion: implications for the therapy of Type 2 diabetes mellitus. Diabetes Metab Res Rev 2001; 17: 164-74.
7. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46 Suppl 1: M9-16.
8. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053-7.
9. Brunelle BL, Llewelyn J, Anderson JH Jr, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726-31.
10. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-8.
11. Danne T, Aman J, Schober E, et al. A Comparison of Postprandial and Preprandial Administration of Insulin Aspart in Children and Adolescents With Type 1 Diabetes. Diabetes Care 2003; 26: 2359-64.
12. American Diabetes Association. Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care 2003; 26: S51-S61.
13. Mensing C, Boucher J, Cypress M, et al. National standards for diabetes self-management education. Task Force to Review and Revise the National Standards for Diabetes Self-Management Education Programs. Diabetes Care 2000; 23: 682-9.
14. Rabasa-Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Diabetes Care 1999; 22: 667-73.
15. Hamet P, Abarca G, Lopez D, et al. Patient self-management of continuous subcutaneous insulin infusion. Diabetes Care 1982; 5: 485-91.
16. Heinemann L, Heise T, Wahl LC, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-9.
17. Slama G, Klein JC, Delage A, et al. Correlation between the nature and amount of carbohydrate in meal intake and insulin delivery by the artificial pancreas in 24 insulin-dependent diabetics. Diabetes 1981; 30: 101-5.
18. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-77.
19. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-8.
20. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001; 161: 2293-300.
21. Bolli GB. Clinical strategies for controlling peaks and valleys: type 1 diabetes. Int J Clin Pract 2002; Suppl: 65-74.
22. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 369-76.
23. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-43.
24. Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-8.
25. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-6.
26. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-9.
27. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49(2 Suppl 1): 9-13.
28. Del Prato S. In search of normoglycemia in diabetes: controlling postprandial glucose. Int J Obest 2002; 26 (Suppl 3): S9-S17.